American College of Cardiology (ACC)

The American College of Cardiology (ACC) is the primary U.S. medical society representing the interests of all cardiology subspecialities. The ACC is very active in setting guidelines for cardiac care, lobbying for supportive government policy and reimbursements, clinician education, managing several key cardiovascular registries and advocating for the transformation of cardiovascular care to improve heart health.

TAVR valve for AR , a recent Edwards acquisition, delivers long-term value
The J-Valve System is associated with positive 10-year outcomes for patients with severe AR, according to new research out of China. It also performs well in patients with severe AS.
SAVR linked to ‘excellent’ long-term survival for patients with bicuspid aortic valves
Survival rates are high for both men and women presenting with BAV disease, according to a new analysis of nearly 28,000 SAVR patients.
IVL may be safer than atherectomy in patients with severely calcified lesions
Researchers explored data from more than 1,000 patients with calcified coronary artery disease who required plaque modification. IVL and atherectomy were linked to comparable success rates, but adverse events were less likely with IVL.
Joint Commission partners with STS, ACC on new cardiac care certification
The new certification is focused on the importance of high-quality care and real-world patient outcomes. It will be based on the same data care teams already submit if they participate in the STS Adult Cardiac Surgery Database, ACC CathPCI Registry or STS/ACC TVT Registry.
FDA-approved PFA system linked to positive 1-year data, ‘impeccable’ durability
The Globe Pulsed Field System, which secured FDA approval in September 2025, features high-density mapping capabilities and a 122-electrode spherical array.

TAVR valve for AR , a recent Edwards acquisition, delivers long-term value

The J-Valve System is associated with positive 10-year outcomes for patients with severe AR, according to new research out of China. It also performs well in patients with severe AS.

SAVR linked to ‘excellent’ long-term survival for patients with bicuspid aortic valves

Survival rates are high for both men and women presenting with BAV disease, according to a new analysis of nearly 28,000 SAVR patients.

The use of intravascular lithotripsy (IVL) during percutaneous coronary intervention (PCI) is still safe and effective when patients present with calcified nodules (CNs), according to new long-term data published in EuroIntervention.[1] Researchers compared outcomes from patients with and without CNs, highlighting key similarities in stent expansion and luminal gain.

IVL may be safer than atherectomy in patients with severely calcified lesions

Researchers explored data from more than 1,000 patients with calcified coronary artery disease who required plaque modification. IVL and atherectomy were linked to comparable success rates, but adverse events were less likely with IVL.

Joint Commission partners with STS, ACC on new cardiac care certification

The new certification is focused on the importance of high-quality care and real-world patient outcomes. It will be based on the same data care teams already submit if they participate in the STS Adult Cardiac Surgery Database, ACC CathPCI Registry or STS/ACC TVT Registry.

mages of the Globe Pulsed Field System courtesy of Kardium

FDA-approved PFA system linked to positive 1-year data, ‘impeccable’ durability

The Globe Pulsed Field System, which secured FDA approval in September 2025, features high-density mapping capabilities and a 122-electrode spherical array.

Treating CLTI with atherectomy fails to improve outcomes—is it worth the cost?

Atherectomy is associated with rising healthcare costs, making it important to learn as much about the procedure's long-term value as possible.

Medical societies, medtech companies and clinicians weigh in as CMS considers sweeping TAVR changes

CMS is considering substantial updates to its TAVR policies, including coverage for asymptomatic patients. Some stakeholders are excited, embracing the possibility of expanded indications and fewer restrictions. Others are concerned that the changes would be too much, too soon.

Abbott’s Navitor TAVR valve linked to positive real-world outcomes

The intra-annular, self-expanding Navitor valve gained FDA approval in 2023 for the treatment of high-risk heart patients with severe aortic stenosis. This analysis explores its early impact on patient care.